Profile-QSAR: A Novel meta-QSAR Method that Combines Activities across the Kinase Family To Accurately Predict Affinity, Selectivity, and Cellular Activity
暂无分享,去创建一个
Eric J. Martin | Prasenjit Mukherjee | Johanna M. Jansen | David C. Sullivan | E. Martin | J. Jansen | Prasenjit Mukherjee
[1] Ariel Fernández,et al. A priori inference of cross reactivity for drug-targeted kinases. , 2006, Journal of medicinal chemistry.
[2] J. Mestres,et al. Conciliating binding efficiency and polypharmacology. , 2009, Trends in pharmacological sciences.
[3] M. Vieth,et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.
[4] C. E. Peishoff,et al. A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.
[5] M. Vieth,et al. Kinomics: characterizing the therapeutically validated kinase space. , 2005, Drug discovery today.
[6] D. Vanderwall,et al. Inhibitors of dihydrodipicolinate reductase, a key enzyme of the diaminopimelate pathway of Mycobacterium tuberculosis. , 2001, Biochimica et biophysica acta.
[7] J. Bajorath. Affinity fingerprints--leading the way? , 2002, Drug discovery today.
[8] J. Goodwin,et al. Physicochemical determinants of passive membrane permeability: role of solute hydrogen-bonding potential and volume. , 2001, Journal of medicinal chemistry.
[9] Claudio N. Cavasotto,et al. Ligand docking and structure-based virtual screening in drug discovery. , 2007, Current topics in medicinal chemistry.
[10] I. Tsigelny,et al. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRβ/B-RAF , 2010, Proceedings of the National Academy of Sciences.
[11] Darren Vs Green,et al. Virtual screening of chemical libraries for drug discovery , 2008, Expert opinion on drug discovery.
[12] J. Bajorath. Computational approaches in chemogenomics and chemical biology: current and future impact on drug discovery , 2008, Expert opinion on drug discovery.
[13] Martyn G. Ford,et al. Selecting Screening Candidates for Kinase and G Protein-Coupled Receptor Targets Using Neural Networks , 2002, J. Chem. Inf. Comput. Sci..
[14] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[15] Hans Briem,et al. Flexsim-X: A Method for the Detection of Molecules with Similar Biological Activity , 2000, J. Chem. Inf. Comput. Sci..
[16] Andreas Bender,et al. "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..
[17] Ian A. Watson,et al. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. , 2009, Journal of medicinal chemistry.
[18] J. Regan,et al. Three-dimensional quantitative structure-activity relationships of 5-HT receptor binding data for tetrahydropyridinylindole derivatives: a comparison of the Hansch and CoMFA methods. , 1993, Journal of medicinal chemistry.
[19] M. Murcko,et al. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. , 2008, Journal of medicinal chemistry.
[20] P. Beroza,et al. Target-related affinity profiling: Telik's lead discovery technology. , 2005, Current topics in medicinal chemistry.
[21] Xiaoyang Xia,et al. Classification of kinase inhibitors using a Bayesian model. , 2004, Journal of medicinal chemistry.
[22] Robert P. Sheridan,et al. QSAR Models for Predicting the Similarity in Binding Profiles for Pairs of Protein Kinases and the Variation of Models between Experimental Data Sets , 2009, J. Chem. Inf. Model..
[23] C. Harris,et al. Chemogenomics: structuring the drug discovery process to gene families. , 2006, Drug discovery today.
[24] E. Jacoby,et al. Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.
[25] Brian K. Shoichet,et al. Molecular Docking and High-Throughput Screening for Novel Inhibitors of Protein Tyrosine Phosphatase-1 B , 2022 .
[26] David M. Rocke,et al. Predicting ligand binding to proteins by affinity fingerprinting. , 1995, Chemistry & biology.
[27] Hans-Joachim Böhm,et al. A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.
[28] G. Bemis,et al. Kinase chemogenomics: targeting the human kinome for target validation and drug discovery. , 2004, Mini reviews in medicinal chemistry.
[29] Eric J. Martin,et al. AutoShim: Empirically Corrected Scoring Functions for Quantitative Docking with a Crystal Structure and IC50 Training Data , 2008, J. Chem. Inf. Model..
[30] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[31] D. C. Sullivan,et al. AutoShim: Empirically Corrected Scoring Functions for Quantitative Docking with a Crystal Structure and IC50 Training Data. , 2008 .
[32] N. Rosen,et al. Resistance to BRAF inhibition in melanomas. , 2011, The New England journal of medicine.
[33] Hugo Kubinyi,et al. Success Stories of Computer‐Aided Design , 2006 .
[34] S. Semus,et al. Modeling the cannabinoid receptor: a three-dimensional quantitative structure-activity analysis. , 1991, Molecular pharmacology.
[35] E. Bradley,et al. Performance of 3D-database molecular docking studies into homology models. , 2004, Journal of medicinal chemistry.
[36] G. Oliva,et al. Virtual screening and its integration with modern drug design technologies. , 2008, Current medicinal chemistry.
[37] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[38] B. Shoichet,et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.
[39] M. Murcko,et al. Chemogenomic approaches to drug discovery. , 2001, Current opinion in chemical biology.
[40] Steven L. Dixon,et al. Bioactive Diversity and Screening Library Selection via Affinity Fingerprinting , 1998, J. Chem. Inf. Comput. Sci..
[41] Ian A. Watson,et al. Chemical fragments as foundations for understanding target space and activity prediction. , 2008, Journal of medicinal chemistry.
[42] I. Muegge,et al. Virtual screening for kinase targets. , 2004, Current medicinal chemistry.
[43] Stephen R. Johnson,et al. Trends in kinase selectivity: insights for target class-focused library screening. , 2011, Journal of medicinal chemistry.
[44] C. Harris,et al. Bringing kinases into focus: efficient drug design through the use of chemogenomic toolkits. , 2006, Current medicinal chemistry.
[45] Eric J. Martin,et al. Surrogate AutoShim: Predocking into a Universal Ensemble Kinase Receptor for Three Dimensional Activity Prediction, Very Quickly, without a Crystal Structure , 2008, J. Chem. Inf. Model..
[46] K. Shokat. Tyrosine kinases: modular signaling enzymes with tunable specificities. , 1995, Chemistry & biology.